Modeling ductal carcinoma in situ: A HER2-Notch3 collaboration enables luminal filling

C. R. Pradeep; W. J. Köstler; M. Lauriola; R. Z. Granit; F. Zhang; J. Jacob-Hirsch; G. Rechavi; H. B. Nair; B. T. Hennessy; A. M. Gonzalez-Angulo; R. R. Tekmal; I. Ben-Porath; G. B. Mills; E. Domany; Y. Yarden

doi:10.1038/onc.2011.279

Modeling ductal carcinoma in situ: A HER2-Notch3 collaboration enables luminal filling

C. R. Pradeep, W. J. Köstler, M. Lauriola, R. Z. Granit, F. Zhang, J. Jacob-Hirsch, G. Rechavi, H. B. Nair, B. T. Hennessy, A. M. Gonzalez-Angulo, R. R. Tekmal, I. Ben-Porath, G. B. Mills, E. Domany, Y. Yarden^*

^*Corresponding author for this work

Department of Developmental Biology and Cancer Research

Research output: Contribution to journal › Article › peer-review

42 Scopus citations

Abstract

A large fraction of ductal carcinoma in situ (DCIS), a non-invasive precursor lesion of invasive breast cancer, overexpresses the HER2/neu oncogene. The ducts of DCIS are abnormally filled with cells that evade apoptosis, but the underlying mechanisms remain incompletely understood. We overexpressed HER2 in mammary epithelial cells and observed growth factor-independent proliferation. When grown in extracellular matrix as three-dimensional spheroids, control cells developed a hollow lumen, but HER2-overexpressing cells populated the lumen by evading apoptosis. We demonstrate that HER2 overexpression in this cellular model of DCIS drives transcriptional upregulation of multiple components of the Notch survival pathway. Importantly, luminal filling required upregulation of a signaling pathway comprising Notch3, its cleaved intracellular domain and the transcriptional regulator HES1, resulting in elevated levels of c-MYC and cyclin D1. In line with HER2-Notch3 collaboration, drugs intercepting either arm reverted the DCIS-like phenotype. In addition, we report upregulation of Notch3 in hyperplastic lesions of HER2 transgenic animals, as well as an association between HER2 levels and expression levels of components of the Notch pathway in tumor specimens of breast cancer patients. Therefore, it is conceivable that the integration of the Notch and HER2 signaling pathways contributes to the pathophysiology of DCIS.

Original language	English
Pages (from-to)	907-917
Number of pages	11
Journal	Oncogene
Volume	31
Issue number	7
DOIs	https://doi.org/10.1038/onc.2011.279
State	Published - 16 Feb 2012

Bibliographical note

Funding Information:
We thank Amit Zeisel and Sara Lavi for help, Brenda Lilly for the Notch3 reporter, and Powel Brown, Corey Speers and the Kleberg Center for Molecular Markers at MD Anderson Cancer Center (CCSG grant NCI CA16672) for providing tumors for the RPPA analysis. We acknowledge research funding by the National Cancer Institute (CA072981, CA121994-01 and CA120248-01), the Israel Cancer Research Fund, Dr Miriam and Sheldon G Adelson Medical Research Foundation, Kekst Family Institute for Medical Genetics, Kirk Center for Childhood Cancer and Immunological Disorders, the Women’s Health Research Center funded by Bennett-Pritzker Endowment Fund, Marvelle Koffler Program for Breast Cancer Research, Leir Charitable Foundation and the MD. Moross Institute for Cancer Research, the Susan G Komen Foundation (FAS0703849 to AMG, BTH and GBM), and a fellowship for PhD track for specialist medical doctors by the Linda and Michael Jacobs Charitable Trust (WJK). YY is the incumbent of the Harold and Zelda Goldenberg Professorial Chair and ED of the Henry J Leir Professorial Chair.

Keywords

DCIS
breast cancer
growth factor
receptor tyrosine kinase
signal transduction
spheroids

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/onc.2011.279

Cite this

Pradeep, C. R., Köstler, W. J., Lauriola, M., Granit, R. Z., Zhang, F., Jacob-Hirsch, J., Rechavi, G., Nair, H. B., Hennessy, B. T., Gonzalez-Angulo, A. M., Tekmal, R. R., Ben-Porath, I., Mills, G. B., Domany, E., & Yarden, Y. (2012). Modeling ductal carcinoma in situ: A HER2-Notch3 collaboration enables luminal filling. Oncogene, 31(7), 907-917. https://doi.org/10.1038/onc.2011.279

@article{f1eca080eca04417bef7f9424c761d4f,

title = "Modeling ductal carcinoma in situ: A HER2-Notch3 collaboration enables luminal filling",

abstract = "A large fraction of ductal carcinoma in situ (DCIS), a non-invasive precursor lesion of invasive breast cancer, overexpresses the HER2/neu oncogene. The ducts of DCIS are abnormally filled with cells that evade apoptosis, but the underlying mechanisms remain incompletely understood. We overexpressed HER2 in mammary epithelial cells and observed growth factor-independent proliferation. When grown in extracellular matrix as three-dimensional spheroids, control cells developed a hollow lumen, but HER2-overexpressing cells populated the lumen by evading apoptosis. We demonstrate that HER2 overexpression in this cellular model of DCIS drives transcriptional upregulation of multiple components of the Notch survival pathway. Importantly, luminal filling required upregulation of a signaling pathway comprising Notch3, its cleaved intracellular domain and the transcriptional regulator HES1, resulting in elevated levels of c-MYC and cyclin D1. In line with HER2-Notch3 collaboration, drugs intercepting either arm reverted the DCIS-like phenotype. In addition, we report upregulation of Notch3 in hyperplastic lesions of HER2 transgenic animals, as well as an association between HER2 levels and expression levels of components of the Notch pathway in tumor specimens of breast cancer patients. Therefore, it is conceivable that the integration of the Notch and HER2 signaling pathways contributes to the pathophysiology of DCIS.",

keywords = "DCIS, breast cancer, growth factor, receptor tyrosine kinase, signal transduction, spheroids",

author = "Pradeep, {C. R.} and K{\"o}stler, {W. J.} and M. Lauriola and Granit, {R. Z.} and F. Zhang and J. Jacob-Hirsch and G. Rechavi and Nair, {H. B.} and Hennessy, {B. T.} and Gonzalez-Angulo, {A. M.} and Tekmal, {R. R.} and I. Ben-Porath and Mills, {G. B.} and E. Domany and Y. Yarden",

note = "Funding Information: We thank Amit Zeisel and Sara Lavi for help, Brenda Lilly for the Notch3 reporter, and Powel Brown, Corey Speers and the Kleberg Center for Molecular Markers at MD Anderson Cancer Center (CCSG grant NCI CA16672) for providing tumors for the RPPA analysis. We acknowledge research funding by the National Cancer Institute (CA072981, CA121994-01 and CA120248-01), the Israel Cancer Research Fund, Dr Miriam and Sheldon G Adelson Medical Research Foundation, Kekst Family Institute for Medical Genetics, Kirk Center for Childhood Cancer and Immunological Disorders, the Women{\textquoteright}s Health Research Center funded by Bennett-Pritzker Endowment Fund, Marvelle Koffler Program for Breast Cancer Research, Leir Charitable Foundation and the MD. Moross Institute for Cancer Research, the Susan G Komen Foundation (FAS0703849 to AMG, BTH and GBM), and a fellowship for PhD track for specialist medical doctors by the Linda and Michael Jacobs Charitable Trust (WJK). YY is the incumbent of the Harold and Zelda Goldenberg Professorial Chair and ED of the Henry J Leir Professorial Chair.",

year = "2012",

month = feb,

day = "16",

doi = "10.1038/onc.2011.279",

language = "אנגלית",

volume = "31",

pages = "907--917",

journal = "Oncogene",

issn = "0950-9232",

publisher = "Springer Nature",

number = "7",

}

TY - JOUR

T1 - Modeling ductal carcinoma in situ

T2 - A HER2-Notch3 collaboration enables luminal filling

AU - Pradeep, C. R.

AU - Köstler, W. J.

AU - Lauriola, M.

AU - Granit, R. Z.

AU - Zhang, F.

AU - Jacob-Hirsch, J.

AU - Rechavi, G.

AU - Nair, H. B.

AU - Hennessy, B. T.

AU - Gonzalez-Angulo, A. M.

AU - Tekmal, R. R.

AU - Ben-Porath, I.

AU - Mills, G. B.

AU - Domany, E.

AU - Yarden, Y.

N1 - Funding Information: We thank Amit Zeisel and Sara Lavi for help, Brenda Lilly for the Notch3 reporter, and Powel Brown, Corey Speers and the Kleberg Center for Molecular Markers at MD Anderson Cancer Center (CCSG grant NCI CA16672) for providing tumors for the RPPA analysis. We acknowledge research funding by the National Cancer Institute (CA072981, CA121994-01 and CA120248-01), the Israel Cancer Research Fund, Dr Miriam and Sheldon G Adelson Medical Research Foundation, Kekst Family Institute for Medical Genetics, Kirk Center for Childhood Cancer and Immunological Disorders, the Women’s Health Research Center funded by Bennett-Pritzker Endowment Fund, Marvelle Koffler Program for Breast Cancer Research, Leir Charitable Foundation and the MD. Moross Institute for Cancer Research, the Susan G Komen Foundation (FAS0703849 to AMG, BTH and GBM), and a fellowship for PhD track for specialist medical doctors by the Linda and Michael Jacobs Charitable Trust (WJK). YY is the incumbent of the Harold and Zelda Goldenberg Professorial Chair and ED of the Henry J Leir Professorial Chair.

PY - 2012/2/16

Y1 - 2012/2/16

N2 - A large fraction of ductal carcinoma in situ (DCIS), a non-invasive precursor lesion of invasive breast cancer, overexpresses the HER2/neu oncogene. The ducts of DCIS are abnormally filled with cells that evade apoptosis, but the underlying mechanisms remain incompletely understood. We overexpressed HER2 in mammary epithelial cells and observed growth factor-independent proliferation. When grown in extracellular matrix as three-dimensional spheroids, control cells developed a hollow lumen, but HER2-overexpressing cells populated the lumen by evading apoptosis. We demonstrate that HER2 overexpression in this cellular model of DCIS drives transcriptional upregulation of multiple components of the Notch survival pathway. Importantly, luminal filling required upregulation of a signaling pathway comprising Notch3, its cleaved intracellular domain and the transcriptional regulator HES1, resulting in elevated levels of c-MYC and cyclin D1. In line with HER2-Notch3 collaboration, drugs intercepting either arm reverted the DCIS-like phenotype. In addition, we report upregulation of Notch3 in hyperplastic lesions of HER2 transgenic animals, as well as an association between HER2 levels and expression levels of components of the Notch pathway in tumor specimens of breast cancer patients. Therefore, it is conceivable that the integration of the Notch and HER2 signaling pathways contributes to the pathophysiology of DCIS.

AB - A large fraction of ductal carcinoma in situ (DCIS), a non-invasive precursor lesion of invasive breast cancer, overexpresses the HER2/neu oncogene. The ducts of DCIS are abnormally filled with cells that evade apoptosis, but the underlying mechanisms remain incompletely understood. We overexpressed HER2 in mammary epithelial cells and observed growth factor-independent proliferation. When grown in extracellular matrix as three-dimensional spheroids, control cells developed a hollow lumen, but HER2-overexpressing cells populated the lumen by evading apoptosis. We demonstrate that HER2 overexpression in this cellular model of DCIS drives transcriptional upregulation of multiple components of the Notch survival pathway. Importantly, luminal filling required upregulation of a signaling pathway comprising Notch3, its cleaved intracellular domain and the transcriptional regulator HES1, resulting in elevated levels of c-MYC and cyclin D1. In line with HER2-Notch3 collaboration, drugs intercepting either arm reverted the DCIS-like phenotype. In addition, we report upregulation of Notch3 in hyperplastic lesions of HER2 transgenic animals, as well as an association between HER2 levels and expression levels of components of the Notch pathway in tumor specimens of breast cancer patients. Therefore, it is conceivable that the integration of the Notch and HER2 signaling pathways contributes to the pathophysiology of DCIS.

KW - DCIS

KW - breast cancer

KW - growth factor

KW - receptor tyrosine kinase

KW - signal transduction

KW - spheroids

UR - http://www.scopus.com/inward/record.url?scp=84857112420&partnerID=8YFLogxK

U2 - 10.1038/onc.2011.279

DO - 10.1038/onc.2011.279

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 21743488

AN - SCOPUS:84857112420

SN - 0950-9232

VL - 31

SP - 907

EP - 917

JO - Oncogene

JF - Oncogene

IS - 7

ER -

Modeling ductal carcinoma in situ: A HER2-Notch3 collaboration enables luminal filling

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this